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Central nervous system involvement in mitochondrial disease
Mitochondrial respiratory chain defects are an impor-
tant cause of inherited disorders affecting approxi-
mately 1 in 5000 people in the UK population.
Collectively these disorders are termed ‘mitochondrial
diseases’ and they result from either mitochondrial
DNA mutations or defects in nuclear DNA. Although
they are frequently multisystem disorders, neurological
deficits are particularly common, wide-ranging and dis-
abling for patients. This review details the manifold
neurological impairments associated with mitochon-
drial disease, and describes the efforts to understand
how they arise and progressively worsen in patients
with mitochondrial disease. We describe advances in
our understanding of disease pathogenesis through
detailed neuropathological studies and how this has
spurred the development of cellular and animal models
of disease. We underscore the importance of continued
clinical, molecular genetic, neuropathological and ani-
mal model studies to fully characterize mitochondrial
diseases and understand mechanisms of neurodegener-
ation. These studies are instrumental for the next phase
of mitochondrial research that has a particular empha-
sis on finding novel ways to treat mitochondrial disease
to improve patient care and quality of life.
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Mitochondria
Mitochondria are the main source of energy, in the
form of adenosine triphosphate (ATP), in neurons, but
they also play important roles in initiating apoptosis,
iron-sulphur cluster biogenesis and calcium buffering.
Mitochondria house the machinery necessary to per-
form oxidative phosphorylation (OXPHOS) within the
inner mitochondrial membrane. This machinery com-
prises an electron transport chain (ETC) which is made
up of four multisubunit complexes (complex I–IV) and
two mobile electron carriers (ubiquinone and
cytochrome c) that are thought to form supercomplexes
[1]. The ETC allows the transfer of electrons through
the complexes and the translocation of protons into the
intermembrane space. This proton gradient is har-
nessed by ATP synthase (complex V) to synthesize
ATP.
The OXPHOS system is under dual genetic control of
the mitochondrial DNA (mtDNA) and nuclear DNA
(nDNA). mtDNA exists as a multiple copy circular dou-
ble-stranded 16.6 kb DNA molecule and encodes for 13
polypeptide proteins for the ETC and the necessary
RNA machinery [2 ribosomal RNAs (rRNAs) and 22
transfer RNAs (tRNAs)] required for their synthesis
within the mitochondria [2]. The remaining proteins
subunits and assembly factors are encoded by the
nDNA and imported into mitochondria. In addition to
this, the nDNA encodes for proteins involved in mtDNA
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maintenance and expression and mitochondrial dynam-
ics, including mitochondrial fission and fusion.
Mitochondrial genetics and disease
Mitochondrial disorders represent a common group of
human genetic diseases that result from a primary
defect of mitochondrial OXPHOS. Impaired energy gen-
eration due to a failure of OXPHOS can therefore result
from a genetic defect arising in either the mtDNA or
nDNA. MtDNA mutations may either be in the form of
point mutations, such as the most common mtDNA
mutation m.3243A>G which affects mt-tRNALeu, or
large-scale mtDNA rearrangements, including single
large-scale mtDNA deletions associated with Kearns–
Sayre syndrome (KSS). MtDNA is strictly inherited
through the maternal line [3], and can exist in a state
of homoplasmy (comprising solely wild type or mutated
mtDNA molecules) or heteroplasmy (mixture of wild
type and mutated mtDNA). The heteroplasmy level of
mutated mtDNA in cell is important for determining
whether there is disruption to OXPHOS that results in
a detectable biochemical defect.
The heterogeneous nature of mitochondrial disease
means that patients may be affected at any age and
with multisystem involvement that does not always
correlate with genotype, and so this presents a major
diagnostic and treatment challenge for patient manage-
ment. Certain mtDNA mutations are associated with
specific syndromes, however, a single mutation can
cause several different phenotypes depending on the
segregation of the mutation and heteroplasmy level.
Perhaps the best example of this is the m.3243A>G
MT-TL1 mutation which was first described in relation
to the classic mitochondrial encephalopathy with lactic
acidosis and stroke-like episodes (MELAS) syndrome
[4]. However, the m.3243A>G mutation can also lead
to chronic progressive external opthalmoplegia (CPEO)
and maternally inherited deafness and diabetes. Cur-
rent estimates of the prevalence of mtDNA mutations
contributing to human disease in the north east of
England affect 1 in 5000 individuals [5,6].
The emergence of next generation sequencing has
led to a rapid expansion in the number of nDNA muta-
tions being identified [7]. Nuclear encoded DNA defects
affecting mtDNA maintenance, OXPHOS assembly and
structure and mitochondrial dynamics are predicted to
affect approximately 2.9 per 100 000 of the adult
general population [5]. One of the most common nDNA
defects, are mutations in the POLG gene that encodes
for the sole mtDNA polymerase c and is responsible for
replication of the mitochondrial genome. POLG muta-
tions result in a range of different clinical phenotypes
either with an early onset, such as in Alpers’ syn-
drome, or late onset as seen in patients with CPEO,
myoclonic epilepsy myopathy sensory ataxia (MEMSA)
and ataxia neuropathy spectrum (ANS) and these are
associated with either accumulation of multiple mtDNA
deletions and/or depletion of mtDNA content within
individual neurons [8].
Neurological symptoms and
neuropathology
Despite only weighing 2% of total body mass, the brain
consumes 20% of oxygen and 50% glucose supplied
through delivery from the vasculature and is used to
drive aerobic respiration within mitochondria [9]. Neu-
rons are heavily dependent on mitochondria for the
production of energy for a number of processes under-
pinning neurotransmission including the regulation of
the sodium potassium ATPase pump, regulation of
intracellular calcium concentration and exocytosis/re-
cycling of synaptic vesicles [10,11]. Glial cells, such as
astrocytes, play important roles in glutamate metabo-
lism, and ion and water homeostasis and are dependent
on OXPHOS but also contain stores of glycogen for
energy metabolism [12]. It is for these reasons, the
neuronal cells are especially vulnerable to deficits in
energy generation within mitochondria and neurologi-
cal deficits are the most common symptoms reported in
patients with mitochondrial disease and are probably
the largest contributor to morbidity and mortality. We
discuss the common neurological features and associ-
ated neuropathological findings.
Cerebellar ataxia
Cerebellar ataxia is common in both adult and paedi-
atric patients with mitochondrial disease [13–15]. A
recent UK cohort study revealed that out of 345 adult
patients with mitochondrial disease, 225 were affected
by cerebellar ataxia that is progressive in nature.
Ataxia is reported in patients harbouring many differ-
ent mtDNA mutations, including the common tRNA
point mutations MT-TL1 and MT-TK and also single
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large-scale mtDNA deletions. Cerebellar changes are
also reported in patients harbouring nDNA mutations,
including RARS2 [16], C10orf2 [17] and POLG muta-
tions [18]. In patients harbouring POLG defects, ataxia
may be reported as one of the prevailing neurological
features and is frequently reported in patients with
MEMSA [19,20] and ANS. The main neuroradiological
finding is cerebellar volume loss including progressive
cerebellar atrophy and to a lesser extent cerebellar
hypoplasia [14,21].
Neuropathology studies The major neuropathological
findings include cerebellar atrophy, microinfarcts,
Purkinje cell loss and morphological changes, including
axonal torpedoes and abnormal dendritic arborisations,
in remaining neurons [13,22–24]. Patients harbouring
MT-TL1 show Purkinje cell vulnerability and a high
frequency of microinfarcts (or ischaemic-like lesions)
affecting the cerebellar cortex. The aetiology of
microinfarcts is not well understood, however, it might
be the result of energy deficiency within neurons
combined with microvascular abnormalities which lead
to localized necrotic cell death [25,26]. The pattern of
olivo-cerebellar pathway vulnerability in patients
harbouring MT-TK and POLG mutations are very
similar. Patients with these genetic defects also
demonstrate ischaemic-like lesions that histologically
resemble those seen in MT-TL1. Surviving neurons
show a profound loss of complex I subunits indicative
of complex I deficiency [13,17]. It is not understood if
neurons that harbour such a severe complex I defect
are capable of normal neurotransmission and why they
do not undergo cell death. While cell loss and synaptic
changes are detected in patients harbouring a single
large-scale mtDNA deletion associated with KSS
[13,27,28], the major neurohistopathological hallmark
is that of a myelinopathy in the deep white matter of
the cerebellum, which is widespread throughout the
CNS, and this is attributed to specific changes to the
oligodendrocyte populations [29].
Extrapyramidal features
Extrapyramidal features, including dystonia, akathisia
(motor restlessness), Parkinsonism and tardive dyskine-
sia, have been described in patients harbouring POLG
mutations. In 2004, Luoma and colleagues reported
the first description of Parkinsonism in a patient with
autosomal dominant PEO due to mutated POLG [30].
As then parkinsonism has been shown to co-segregate
with the POLG defect [30,31], respond to levo-DOPA
treatment [30] and the brains of the patients show
reduced dopamine-uptake in the striatum following
DaT scan [32–34].
Leigh syndrome is a progressive neurodegenerative
condition affecting infants owing to mutations affecting
mtDNA, including mt-mRNA and mt-tRNA mutations,
and nDNA defects [35,36]. Clinical symptoms include
developmental delay, hypotonia, dystonia and failure to
thrive. The clinical course may be varied, however,
patients often present with respiratory abnormalities,
nystagmus and ataxia. Characteristic neuroradiological
features include bilateral symmetric lesions affecting
the brain stem and basal ganglia which are likely to
contribute to the dystonia in these patients.
Neuropathology studies In idiopathic Parkinson’s
disease (iPD), complex I deficiency and accumulation of
mtDNA deletions have been detected in substantia
nigra pars compacta (SNpc) neurons [37,38]. In a
recent study, mtDNA deletions were also found in SNpc
neurons from patients with POLG mutations that were
very similar to those seen in iPD [39]. Changes in SNpc
neurons from patients harbouring POLG and C10orf2
mutations showed neuronal loss without alpha-
synuclein or Lewy bodies, whereas remaining neurons
demonstrated a preferential complex I deficiency [40].
Another study of patients with POLG mutations
demonstrated severe nigrostriatal degeneration with
decreased mtDNA in remaining neurons [41]. In both
studies, the degree of nigrostriatal degeneration did not
correlate with clinical signs of Parkinsonism.
The neuropathological features of Leigh syndrome
include symmetrical vasculo-necrotic lesions affecting
the substania nigra, putamen in the basal ganglia
and thalamus or sub-thalamic nuclei. These lesions
are characterized by spongiform changes, and cyto-
toxic oedema and also increased capillary prominence
[42].
Peripheral neuropathies
Peripheral nerve involvement is frequent in mitochon-
drial disease, and might define the clinical picture in a
number of patients with intergenomic signalling defects
causing multiple mtDNA deletions and mtDNA
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depletion. This includes ANS due to POLG mutations
where the neuropathy is mainly sensory with a loss of
proprioception and vibration sense and touch and pin-
prick sensory changes with a varying degree of distal
muscle weakness. Nerve conduction studies show
decreased or absent sensory action potentials and vary-
ing motor involvement [43]. In almost all patients with
mitochondrial neurogastrointestinal encephalopathy,
due to mutations in TYMP, the neuropathy is predomi-
nantly demyelinating with slowed conduction velocities
and axonal degeneration and segmental demyelination
in biopsied nerves [44,45]. Charcot-Marie-Tooth heredi-
tary neuropathy Type 2A (CMT2A) disease is due to
mutations in MFN2, which encodes a protein involved
in mitochondrial dynamics, and this leads to a progres-
sive early onset axonal neuropathy [46]. Peripheral
neuropathy might also be present in other disorders
due to mtDNA mutations, including point mutations
m.8344A>G and m.3243A>G, in conjunction with
other neurological features [47,48].
Neuropathology studies Relatively few studies have
explored neuropathological features associated with
peripheral neuropathy, however, a recent electro-
physiological and neuropathological study provided
evidence of a sensory neuronopathy in patients with
POLG mutations, and confirmed a loss of sensory
neurons and respiratory chain deficiency in remaining
cells in the dorsal root ganglia. In this patient,
respiratory chain deficiency was associated with
lowered mtDNA content in remaining neurons [43].
This may explain the common finding of a loss of fibre
tracts from the dorsal column in patients with a
peripheral neuropathy [43,49].
Epilepsy
Epilepsy may be a presenting feature, such as in myo-
clonic epilepsy ragged red fibres (MERRF) or MEMSA,
or emerge on the background of multiple neurological
impairments, such as in MELAS, and seizures may
occur in any seismology or classification. A recent
study identified that approximately 23.1% of 182
adult patients with genetically-defined mitochondrial
disease in a UK cohort develop epilepsy, and that
approximately 34.9% of patients with MT-TL1 muta-
tion will develop epilepsy and of these 17.5% also
develop stroke-like episodes. In these patients, epilepsy
may be classified as focal motor seizures with or with-
out a loss of consciousness. While in patients harbour-
ing MT-TK, epilepsy affects 92% of patients and is
usually progressive myoclonus and generalized tonic
clonic seizures [50]. Epilepsy occurring in infancy is
associated with a particularly poor prognosis with a
50% fatality rate in children 9 months after a diagno-
sis of epilepsy being made [51]. Alpers’ syndrome
affects neonates and infants who may present with
refractory seizures, developmental delay and liver
involvement. The epilepsy in these patients are partic-
ularly devastating as they may develop status epilepti-
cus, which can be focal or generalized, and from
which they may never recover [52]. Management of
epilepsy in mitochondrial disease is often challenging.
Neuropathology It is difficult to pinpoint neuropatho-
logical changes specifically associated with seizure
activity in patients with mitochondrial disease as there
are often multiple neurological impairments coinciding
with the epilepsy and it is difficult to dissect primary
changes vs. secondary changes. Often seizures associated
with stroke-like episodes reveal foci of necrosis affecting
the cerebral cortex, and these will be discussed in further
detail under ‘seizure-associated stroke-like episodes’. The
importance of neuronal energy depletion in epilepsy is
underscored by the high prevalence of epilepsy in
mitochondrial disease. A vulnerability of cortical
inhibitory interneurons has recently been shown in post-
mortem tissues from patients with mitochondrial disease
with evidence of combined complex I and IV defects and
reduced interneuron densities (Figure 1). The
identification of combined respiratory chain defects in
this study utilizes a novel immunofluorescent assay to
interrogate mitochondrial respiratory chain subunit
abundance in conjunction with a mitochondrial mass
marker within specific neuronal populations, which
allows a more precise and accurate method of
quantification [53]. The combined respiratory chain
defect in interneurons is proposed to influence neuronal
networks which could contribute to lowered threshold
for seizure activity and permit neuronal hyperexcitability
but this remains to be substantiated [54]. Mitochondrial
abnormalities have been detected in both human tissues
and animal models of temporal lobe epilepsy with
detection of mitochondrial ultrastructural pathology,
impairment of complex I in the CA3 region of the
hippocampus [55,56].
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Seizure-associated stroke-like episodes
Stroke-like episodes are often reported in patients with
mitochondrial disease and are best defined as an epi-
sode of focal cerebral metabolic crisis. Important trig-
gers that have been recognized include febrile illness,
headaches, seizures and dehydration. Stroke-like epi-
sodes are one of the main syndromic features of
patients with MELAS due to the MT-TL1 mutation, and
in these patients the standard diagnostic criteria
includes clinical features, onset usually before aged
40 years, neuroradiological imaging evidence and sei-
zures [57]. However, it not only includes patients with
the MT-TL1 mutation that are affected by stroke-like
episodes but also includes patients harbouring muta-
tions in POLG [58], FBXL4 [59] and other mtDNA
point mutations, including MT-TK mutations [60]. In
this review, we refer to stroke-like episodes as seizure-
associated stroke-like episodes because seizures may sig-
nal/be concomitant to the onset of stroke-like episodes
in patients and are often detected on electroencephalo-
gram (EEG) [61].
During the prodromal phase, patients might develop
positive visual phenomena including phosphenes and
moving objects and often associated with a throbbing
headache. As the stroke-like episodes evolve, patients
can develop negative visual phenomena including
homonymous hemianopia and cortical blindness; defi-
cits that may become fixed with time. Stroke-like epi-
sodes are detected using magnetic resonance imaging
(MRI) as T2-weighted hyperintensities which are typi-
cally in posterior brain regions though not associated
with any major vascular territories. Recently there
have been a number of radiological studies to deter-
mine the mechanisms contributing to the onset of a
stroke-like episode and also to monitor its progression
as they can migrate to other regions of the brain.
There is evidence that during preclinical or acute onset
of a stroke-like episode, focal hyperperfusion can be
detected by either arterial spin labelling or SPECT and
can manifest before any structural abnormalities might
be seen on MRI [62–67]. In addition to this, there are
reports of vasodilation following magnetic resonance
angiogram and impaired cerebrovascular reactivity
Figure 1. Mitochondrial respiratory chain defects in inhibitory interneurons in a patient with mitochondrial disease. Inhibitory
interneurons (GAD65-67; blue) from a control subject show good co-localization of a mitochondrial mass marker (porin; magenta) with a
subunit of complex I (NDUFB8; red) and complex IV [cytochrome c oxidase I (COXI); green]. While inhibitory interneurons from a patient
harbouring autosomal recessive mutations in polymerase gamma show decreased expression of both complexes I and IV (marked by
white asterix) relative to the mitochondrial mass marker. Scale bar = 10 lm.
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[68,69]. There are conflicting data around apparent
diffusion coefficient and whether this is reduced, reflect-
ing cytotoxic oedema, or increased, reflecting vasogenic
oedema, in the acute phase of a stroke-like episode
[70–74]. Stroke-like episodes in mitochondrial disease
have a similar manifestation as posterior reversible
encephalopathy syndrome (PRES) where headache,
encephalopathy, seizures and visual disturbances are
common. In PRES, patients typically develop cerebral
oedema in the occipital poles, presumed due to cerebral
autoregulatory failure [75]. Moreover, it has been con-
jectured that the vulnerability of the posterior circula-
tion to the development of oedema maybe due to the
relative reduction in sympathetic innervation of the
posterior circulation [75,76].
The treatment of seizure-associated stroke-like epi-
sodes involves the urgent control of seizures in the
acute phase and then continued anticonvulsants for
the prevention of further seizures and development of
refractory status epilepticus, a widely recognized com-
plication of mitochondrial disease [77,78]. Additional
recent studies advise the implementation of L-arginine
therapy in the acute phase and during the interictal
phases of stroke-like episodes to prevent or decrease the
severity of these episodes in patients with MELAS [79].
The proposed mechanism of action of L-arginine is to
allow the conversion of L-arginine into nitric oxide
(NO) in the vascular endothelium. NO is a potent medi-
ator of vascular smooth muscle relaxation to improve
vasodilation and blood flow in the cerebrovasculature.
Recent studies have shown that serum arginine and
NO levels are depleted in patients with MELAS and that
administration of L-arginine may be beneficial [80,81].
There is a clear need for standardized, serial neu-
roimaging studies of patients with stroke-like episodes
in order to establish specific imaging criteria to accu-
rately detect and monitor stroke-like episodes, especially
when considering therapeutic trials for these patients
where accurate and measurable outcomes are crucial
for determining drug efficacy. Furthermore, there is an
urgent need for effective evidence-based therapeutic
strategies using randomized open-label, multicentre
studies to confirm the efficacy of anticonvulsant drugs
and L-arginine in conjunction with serial neuroimaging
to provide insights into the evolution of lesions to the
brain and influence the implementation of neuroprotec-
tive therapies to prevent the irreversible loss of brain
function.
Neuropathology The most common neuropathological
findings in patients with stroke-like episodes are the
presence of multiple foci of neuronal necrosis (recently
termed focal energy-dependent neuronal necrosis)
affecting the posterior cerebral cortex, basal ganglia
and cerebellum. These areas of chronic necrosis are
ischaemic-like in appearance; exhibiting neuronal cell
loss, destruction of the neuropil and subcortical white
matter accompanied by proliferation of astrocytes and
inflammatory cells (Figure 2), but they do not conform
to major vascular territories. The degree of necrosis
varies according to the severity of the stroke-like
episodes, in terms of whether they were recurrent, or
timing before death. In some patients, laminar cortical
necrosis may be evident affecting cellular layers III and
IV–V, whereas in others the entire cortical ribbon may
be ablated and might reflect a more chronic process.
While the pathological mechanisms underpinning
stroke-like episodes are not clearly defined, unaffected
areas of the brain provide clues with evidence of neu-
ronal respiratory chain defects and angiopathic
changes. There are a number of hypotheses to explain
mechanisms underpinning neurodegeneration occur-
ring during and after a stroke-like event, and these
include: (i) Mitochondrial cytopathic theory, (ii) Mito-
chondrial angiopathic theory and finally and (iii) Neu-
ronal hyperexcitability theory. The mitochondrial
cytopathic theory suggests that respiratory chain
defects and therefore compromised energy production
in neurons or glial cells or a combination of both are
sufficient to cause focal necrosis [82]. The
Figure 2. Focal energy-dependent neuronal necrosis affecting the occipital cortex of a patient harbouring a MT-TK mutation. Focal
neuronal necrosis affects the cortical ribbon (A; cresyl fast violet) causing neuronal cell loss and spongiform degeneration (B; cresyl fast
violet) accompanied by astrogliosis (C; weak expression of GFAP) and inflammation (D; HLA-DP, DQ, DR). Remaining neurons within the
lesion show both complex I expression (E; NDUFB8 – black arrow) and complex I deficiency (E; NDUFB8 – red arrow), whereas
mitochondrial density is maintained in all neurons (F; porin – black arrow). Subcortical white matter shows a loss of myelin (G.i; Loyez)
and axonal loss (H.i; phosphorylated neurofilaments), whereas in unaffected cortical regions myelin (G.ii; Loyez) and axonal density are
maintained (H.i; phosphorylated neurofilaments). Scale bar = 100 lm.
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mitochondrial angiopathic theory is supported by evi-
dence of aggregated, enlarged mitochondria within
smooth muscle and endothelium in the vasculature,
and histochemical data revealing strongly succinate
dehydrogenase-reactive vessels which show an accu-
mulation of mitochondria, similar to ragged red fibres
[83,84]. This might represent a morphological abnor-
mality of the microvasculature which leads to physical
occlusion. There are contradictory reports which sug-
gest that these abnormal mitochondria still retain cyto-
chrome c oxidase (COX) activity, whereas others
suggest COX activity is lost and is associated with high
mutant load in microvessels [25,85]. In the latter stud-
ies, mitochondrial respiratory chain defects affect pial
arterioles and smaller penetrating arterioles which
might compromise cerebrovascular autoregulation and
therefore blood vessel tone. Another proposed mecha-
nism is related to the accumulation of abnormal mito-
chondria within the endothelium and smooth muscle
layers which affects NO-dependent vasodilatory capac-
ity of the small arteries therefore impeding blood flow.
This impaired vasodilation may be corrected through
the use of L-arginine as discussed previously [86]. This
could lead to areas of the brain with impoverished cere-
bral blood flow and certain brain areas vulnerable to
localized ischaemia. Why this occurs with a posterior
predilection is not known, however, the posterior circu-
lation has inadequate sympathetic innervation to medi-
ate autoregulatory control of blood flow [87], this
coupled with an energy crisis in arterioles might be a
factor in causing focal necrotic lesions. The final theory
proposes that neuronal hyperexcitability is responsible
for the lesions as seizures are often detected on EEG
during a stroke-like episode, and neuronal hyperex-
citability will worsen the energy imbalance between
ATP availability and energy requirement, and ulti-
mately lead to neuronal cell death [64,88]. It is likely
that the aetiology of the focal necrotic lesions are mul-
tifactorial, and probably a combination of all three the-
ories influences the emergence of lesions in the brain
(Figure 3).
Cognitive decline and behavioural disturbance
Cognitive impairment and dementia have been fre-
quently in case reports of patients with mitochondrial
disease due to mtDNA mutations, however, there are
very few large-scale longitudinal studies and stan-
dardised criteria to define cognitive impairments. A
neuropsychological study conducted on 16 adult
patients with mitochondrial disease (either due to
MT-TK point mutation, single large-scale mtDNA
deletion or multiple mtDNA deletions) revealed non-
verbal cognitive impairments and verbal short-term
memory deficits, associated with working memory,
with hypometabolism in the temporal lobes on neuro-
radiological imaging [89]. In a separate study,
patients with either a single large-scale deletion or
MT-TL1 point mutation identified focal deficits in
visual construction, attention and abstraction [90]. In
patients harbouring the MT-TL1 mutation, neuropsy-
chological testing provided evidence of a global dete-
rioration in cognition affecting executive function,
attention, language, memory, visuospatial and motor
function [91]. Cerebral lactic acidosis in patients har-
bouring MT-TL1 mutations correlates with neuropsy-
chological scores in patients with or without stroke-
like episodes implying dysfunction in the frontal
domains which is not detected by neuroradiological
imaging [92].
Figure 3. A working hypothesis to dissect out mechanisms underpinning formation of focal neuronal necrotic lesions during stroke-like
episodes. Mitochondrial DNA defects are segregated throughout individual mitochondria and clonally expand to high mutant loads to
cause mitochondrial respiratory chain defects defined by a loss of respiratory chain complex activity. Respiratory chain deficiency
compromises mitochondrial function leading to reduced adenosine triphosphate (ATP) generation, and impaired calcium buffering.
Respiratory chain deficiencies have been documented in multiple cell types within the CNS with neurons, glia and blood vessels (smooth
muscle and endothelial cells) and while the impact on cellular function is not yet fully elucidated, the potential mechanisms are described
here. Respiratory chain deficient inhibitory interneurons could contribute to modified neuronal and synaptic function leading to neuronal
network instability and neuronal hyperexcitability which could in turn lower the threshold for seizure generation. Seizures are commonly
reported in the early phase of a stroke-like episodes and can be detected on electroencephalogram. Respiratory chain deficiencies affecting
glial cells, including astrocytes (deficient – red arrow, intact – black arrow), are also observed which could affect synaptic transmission
(e.g. glutamate metabolism, ionic homeostasis) and contribute to cortical spreading depression. While respiratory chain deficiencies
affecting the CNS vasculature might leading to cerebral auto regulatory failure leading to a mismatch between neuronal activity and
appropriate blood flow. This further worsens the ongoing neuronal insult leading to cytotoxic and vascular oedema, hyperintensities on
magnetic resonance imaging and irreversible cell loss in necrotic lesions.
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Neuropathology There is a paucity of studies correlating
neuropathological changes with cognitive impairments
in mitochondrial disease. Although it is likely that
deterioration in cognition might be attributed to the
presence of necrotic foci which impinge on multiple
circuits involved in cognitive processing, certainly
cognitive decline has been observed in patients without
stroke-like episodes implying that the frontal domains
are affected. Neuropathological studies detect changes in
neuronal populations in patients affected by either
mtDNA or nDNA mutations which could contribute to
cognitive dysfunction in mitochondrial disease. A loss of
calbindin expression in hippocampal neurons without
neuronal loss has been described, and also loss of cortical
inhibitory interneurons and respiratory chain
deficiencies which could certainly contribute to impaired
network activity in the brain [54,93].
Modelling the neurology of mitochondrial
disease
Clinical, molecular genetic and neuropathological stud-
ies have given important insights into the disease
pathogenesis. The application of the knowledge gained
from these studies is now driving the development of
cell and animal model systems to test hypotheses and
adopt a functional approach to understanding mecha-
nisms and evaluate the efficacy of treatment.
Transgenic mouse models
Modelling mtDNA disease has been impeded by the
inability to generate stable mtDNA point mutations in
mice without undergoing a bottleneck effect and loss of
the mutation through successive generations of mice
[94]. Many of the models generated to date have uti-
lized Cre/Lox technology to selectively knockout (KO)
nuclear genes involved in: (i) mtDNA maintenance,
replication, transcription, translation (ii) expression and
assembly of OXPHOS complexes and (iii) mitochondrial
dynamics to evaluate the effect on specific populations
of neurons. A comprehensive description of these mod-
els is beyond the scope of the current review and we
refer readers to a three part review miniseries published
last year which discusses each model in detail [95–97].
Here, we provide a brief overview and examples of
models associated with defects in; (i) mtDNA mainte-
nance and (ii) OXPHOS in certain neuronal
populations. A number of mouse models have been
generated by targeting TFAM which is a nuclear
encoded transcriptional activator which has a number
of roles within the mitochondrion including binding to
the mtDNA promotor to activate mitochondrial tran-
scription, provides RNA primers to facilitate mtDNA
replication and also plays a histone-like role by coating
the mtDNA [98]. There are two models which have
used neuronal-specific KO of TFAM, including forebrain
neurons using a CaMKIIa-Cre [Mitochondrial Late
Onset Neurodegeneration (MILON) mice] and dopamin-
ergic neurons using a DAT-Cre (MitoPark mice) which
lead mtDNA depletion in the targeted neurons. The
MILON mice show a reduction in mtDNA copy number
in neocortex at 2 months of age and develop a pheno-
type at age 5–6 months whereby they severely deterio-
rate and die within 2–3 weeks after onset [99].
Neuropathologically the neocortex undergoes severe
degeneration and loss of organization, whereas in the
hippocampus, CA1 is absent with a profound loss of
pyramidal cells, CA2 is intact and CA3 is slightly
affected. Chimeric MILON mice were generated to study
the effects of mosaic pattern of wild type and mtDNA
depletion in forebrain neurons. They revealed that low
levels (20%) of respiratory chain deficiency were suffi-
cient to produce behavioural abnormalities, whereas
higher levels (80%) of respiratory chain deficiency were
sufficient to induce trans-neuronal degeneration events
[100].
The MitoPark mice harbour dopaminergic neuron-
specific KO of TFAM and develop a progressive
Parkinson-like phenotype at 12 weeks of age with
motor deficits, dopamine depletion and SNpc degenera-
tion [101]. In asymptomatic mice aged 6–8 weeks,
electrophysiological experiments reveal subtle changes
in nigrostriatal function with an absence of pacemaker
activity in SNpc neurons and impaired dopamine
release from their axonal terminals [102].
The second group of transgenic mouse models we
discuss are those associated with defects in OXPHOS
either due to abolished complex subunit or assembly
unit expression. There are a number of model which
target subunits associated with complex I as complex I
deficiencies are frequently detected in mitochondrial
disease. A neuronal and glial-specific KO (using a nes-
tin-Cre) of NDUFS4 (NADH:ubiquinone oxidoreductase
subunit S4), which encodes for a nuclear-encoded
accessory subunit of complex I, has been generated.
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This mouse shows rapidly progressive gait impairments,
breathing difficulties and death by 7 weeks of age and
therefore resembles Leigh syndrome. Neuropathological
features include complex I deficiency and progressive
degeneration in the form of spongiosis and lesions
within the olfactory bulb, cerebellum and vestibular
nuclei accompanied by progressive glial activation and
inflammation [103,104]. A recent study has investi-
gated hypoxia as a possible treatment strategy for ame-
liorating disease progression; NDUFS4 KO mice were
exposed to chronic hypoxia (11% oxygen) environment
showed extended lifespan with improved motor coordi-
nation and reduced neuroinflammation upon neuro-
histopathological assessment [105].
Mice harbouring NDUFA5 (NADH:ubiquinone oxidore-
ductase subunit A5) KO, a nuclear-encoded structural
subunit of complex I, in forebrain neurons (using
CaMKIIa-Cre) were healthy until 10–11 months of age
when they became lethargic, demonstrated a loss of
motor coordination and hindlimb clasping. These mice
showed only a mild encephalopathy with evidence of
complex I deficient neurons without evidence of neu-
rodegeneration which the authors suggest might be
related to compensatory processes [106].
Recently, forebrain neuron-specific (using CaMKIIa-
Cre) KOs for RISP (encoding for a catalytic subunit of
complex III; Reiske iron-sulphur cluster protein) and
COX10 (encoding an accessory protein involved in
assembly of COX) have been created to understand
more about the selective brain involvement in mito-
chondrial disease. These studies revealed that the RISP-
KO mice developed a rapid phenotype aged 2 months
with poor rotarod performance with a rapid disease
progression and died aged 3–3.5 months. Evaluation of
CNS tissues confirmed complex III deficiency and high
levels of oxidative stress in remaining neurons, particu-
larly affecting the piriform cortex. While in the COX10-
KO mice, rotarod performance was poor aged 3 months
but they survived until aged 8–12 months with a vul-
nerability of the cingulate cortex and oxidative stress in
remaining neurons [107].
Induced pluripotent stem cells
Induced pluripotent stem cells (iPSC) hold the potential
for in vitro disease modelling, drug screening and cell-
replacement therapies. iPSCs constitute cells which are
capable of self-renewal and can differentiate into any
cell type and are generated by reprogramming patient
fibroblasts with pluriopotency associated transcription
factors. In recent years, a number of studies have uti-
lized patient-derived iPSC to understand mechanisms of
mitochondrial disease exploiting the main advantages
of (i) maintaining the nuclear genetic background of
the patient, and (ii) differentiation into disease-specific
tissue- or cell-type, e.g. postmitotic neurons. There are
some caveats associated with the study of iPSCs includ-
ing the acquisition of genome instability during culture
[108], the alteration of mitochondrial morphology with
rounded appearance and poor cristae structure, low
mtDNA copy number and respiratory capacity to facili-
tate the metabolic switch to glycolysis. In addition,
impaired mtDNA integrity may be a by-product of cel-
lular reprogramming [109]. There have been a number
of studies utilizing iPSCs to understand pathogenetic
mechanisms in mitochondrial disease, and these are
discussed in more detail in a recent review by Hata-
keyama and colleagues [110].
Induced pluripotent stem cells have been derived
from fibroblasts from patients with MELAS due to the
m.3243A>G mutation and two cell lines were gener-
ated; one harbouring high heteroplasmy levels (>80%)
and the other which was low heteroplasmy levels (un-
detectable). Following differentiation into neurons, the
high heteroplasmy line showed downregulation of com-
plex I and an increase in mitophagy [111]. Another
study that investigated fibroblasts from a patient with
MELAS created iPSC harbouring the m.13513G>A
mutation at heteroplasmic levels (50–60%) and a
mutation-free cell line. Heteroplasmic cell lines showed
a decline in heteroplasmy levels with long-term mainte-
nance in culture [112]. In a recent study, cellular
homoplasmy for the m.8993T>A mutation associated
with Leigh syndrome was genetically corrected using
somatic cell nuclear transfer [113].
Future directions/studies
Unlike other neurodegenerative diseases, brains from
patients with mitochondrial disease show atrophy and
severe neuronal cell loss that this is not associated with
any extra- or intracellular accumulation of misfolded
proteins. The salient neuropathological features are the
decrease or absence of mitochondrial respiratory chain
subunits, particularly involving subunits comprising
complex I, and high ratio mutated mtDNA to wild type
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mtDNA in surviving neurons. The future of mitochon-
drial research should aim to prevent the irreversible
brain loss and neurological disability in these patients.
Post-mortem human brain studies are invaluable for
characterizing the chronic neurodegenerative changes,
and new techniques, such as CLARITY [114,115], will
dramatically improve our understanding of disease
pathogenesis. However, our neuropathological studies
can be strengthened by linking to patient iPSCs and
transgenic mouse models to interrogate functional sys-
tems and enhance our understanding of progressive
mechanisms of degeneration and facilitate the develop-
ment of better-directed therapeutic intervention.
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